CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.9%

CRISPR Therapeutics AG (NASDAQ:CRSPGet Free Report)’s share price was down 0.9% during mid-day trading on Monday . The company traded as low as $66.50 and last traded at $67.52. Approximately 397,058 shares traded hands during trading, a decline of 80% from the average daily volume of 1,941,086 shares. The stock had previously closed at $68.16.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on CRSP shares. TheStreet raised shares of CRISPR Therapeutics from a “d+” rating to a “c” rating in a report on Friday, February 23rd. TD Cowen lowered shares of CRISPR Therapeutics from a “market perform” rating to an “underperform” rating and set a $30.00 price objective for the company. in a report on Monday, December 11th. Truist Financial reissued a “buy” rating on shares of CRISPR Therapeutics in a report on Friday, December 8th. Wolfe Research started coverage on shares of CRISPR Therapeutics in a report on Thursday, February 15th. They issued a “peer perform” rating for the company. Finally, Royal Bank of Canada upped their price objective on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the company a “sector perform” rating in a report on Thursday, February 22nd. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $74.75.

Get Our Latest Stock Analysis on CRISPR Therapeutics

CRISPR Therapeutics Price Performance

The company has a market cap of $5.20 billion, a PE ratio of -33.18 and a beta of 1.76. The company’s 50 day simple moving average is $74.05 and its two-hundred day simple moving average is $62.26.

CRISPR Therapeutics (NASDAQ:CRSPGet Free Report) last issued its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.15 by $0.95. The business had revenue of $201.20 million for the quarter, compared to analyst estimates of $148.72 million. The firm’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.41) EPS. Sell-side analysts expect that CRISPR Therapeutics AG will post -6.24 EPS for the current fiscal year.

Insider Transactions at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, General Counsel James R. Kasinger sold 1,913 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total value of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel James R. Kasinger sold 2,801 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $78.26, for a total transaction of $219,206.26. Following the completion of the sale, the general counsel now directly owns 60,070 shares in the company, valued at approximately $4,701,078.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 134,410 shares of company stock valued at $9,234,677. 4.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Newbridge Financial Services Group Inc. increased its stake in CRISPR Therapeutics by 49.9% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 1,076 shares of the company’s stock valued at $67,000 after purchasing an additional 358 shares during the last quarter. Nomura Holdings Inc. purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $433,000. HighPoint Advisor Group LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter worth approximately $270,000. Vanguard Group Inc. grew its position in shares of CRISPR Therapeutics by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 1,590,651 shares of the company’s stock worth $99,575,000 after acquiring an additional 51,926 shares during the last quarter. Finally, Greenwood Capital Associates LLC grew its position in shares of CRISPR Therapeutics by 23.8% during the fourth quarter. Greenwood Capital Associates LLC now owns 6,801 shares of the company’s stock worth $426,000 after acquiring an additional 1,306 shares during the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

CRISPR Therapeutics Company Profile

(Get Free Report)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Recommended Stories

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.